STAT5: A Target of Antagonism by Neurotropic Flaviviruses
M. G. Zimmerman, J. R. Bowen, C. E. McDonald, E. Young, R. S. Baric, B. Pulendran, M. S. Suthar
Abstract
Flaviviruses are a diverse group of arthropod-borne viruses responsible for numerous significant public health threats; therefore, understanding the interactions between these viruses and the human immune response remains vital. Earlier work has found that WNV and ZIKV infect human DCs and can block antiviral immune responses in DCs. Previously, we used mRNA sequencing and weighted gene co-expression network analysis (WGCNA) to define molecular signatures of antiviral DC responses following activation of innate immune signaling (RIG-I, MDA5, or type I IFN signaling) or infection with WNV. Using this approach, we found that several genes involved in T cell co-signaling and antigen processing were not enriched in DCs during WNV infection. Using cis-regulatory sequence analysis, STAT5 was identified as a regulator of DC activation and immune responses downstream of innate immune signaling that was not activated during either WNV or ZIKV infection. Mechanistically, WNV and ZIKV actively blocked STAT5 phosphorylation downstream of RIG-I, IFN{beta}, and IL-4, but not GM-CSF signaling. Unexpectedly, dengue virus serotypes 1-4 (DENV1-4) and the yellow fever 17D vaccine strain (YFV-17D) did not antagonize STAT5 phosphorylation. In contrast to WNV, ZIKV inhibited JAK1 and TYK2 phosphorylation following type I IFN treatment, suggesting divergent mechanisms used by these viruses to inhibit STAT5 activation. Combined, these findings identify STAT5 as a target of antagonism by specific pathogenic flaviviruses to subvert the immune response in infected DCs.\n\nImportanceFlaviviruses are a diverse group of insect-borne viruses responsible for numerous significant public health threats. Previously, we used a computational biology approach to define molecular signatures of antiviral DC responses following activation of innate immune signaling or infection with WNV. In this work, we identify STAT5 as a regulator of DC activation and antiviral immune responses downstream of innate immune signaling that was not activated during either WNV or ZIKV infection. WNV and ZIKV actively blocked STAT5 phosphorylation downstream of RIG-I, IFN{beta}, and IL-4, but not GM-CSF signaling. However, other related flaviviruses, dengue virus serotypes 1-4 and yellow fever 17D vaccine strain, did not antagonize STAT5 phosphorylation. Mechanistically, WNV and ZIKV showed differential inhibition of Jak kinases upstream of STAT5, suggesting divergent countermeasures to inhibit STAT5 activation. Combined, these findings identify STAT5 as a target of antagonism by specific pathogenic flaviviruses to subvert antiviral immune responses in human DCs.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ISG15/USP18/STAT2 is a molecular hub regulating autocrine IFN I-mediated control of Dengue and Zika virus replication
C. E. Espada, E. L. da Rocha, … D. S. Mansur·bioRxiv·Nov 1, 2023
- T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species.
A. Grifoni, H. Voic, … A. Sette·bioRxiv·Jan 17, 2020
- Nuclear dengue virus NS5 antagonizes expression of PAF1-dependent immune response genes
M. J. Petit, M. W. Kenaston, … P. S. Shah·bioRxiv·Apr 6, 2021
- Flavivirus prM interacts with MDA5 and MAVS to inhibit RLR antiviral signaling
- Tick-borne flavivirus NS5 antagonizes interferon signaling by inhibiting the catalytic activity of TYK2
S. Gracias, M. Chazal, … N. Jouvenet·bioRxiv·Sep 7, 2023
- Disrupting IFIT1-STAT2 viral evasion synergy yields live-attenuated flavivirus with enhanced immune priming
Amporn Suphatrakul, Warangkana Chantima, … Bunpote Siridechadilok·bioRxiv·Jun 5, 2026